TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Cervical Preparation of Abortions Under Paracervical Block in the First Trimester:

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~aged 18 or over with a single intra uterine pregnancy whose term is between 6 and 14 weeks the day of the abortion estimated by ultrasound by a measurement of the cranio-caudal length between 5 and 84 millimeters surgical abortion under local anesthesia informed written consent~Exclusion Criteria:~minor multiple pregnancy Uterine malformation coagulation disorder defined by biological parameters (TP\<70%, TCA patient / control ratio \< 1.20) Allergy or hypersensitivity to any of the active substance or to any of the excipients Contraindication to mifepristone chronic renal insufficiency severe asthma uncontrolled by treatment hereditary porphyria allergy to the active substance or to any of the excipients; not affiliated to the social security system; no informed consent. Suspicion of ectopic pregnancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mifépristone group (Type: EXPERIMENTAL): None
- misoprostol group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mixed Reality Based System to Manage Phantom Pain Phantom Pain for Patients With Lower Limb Amputation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, over the age of 18 with lower limb amputations (greater than 3 months post surgery) with phantom limb pain~Exclusion Criteria:~* Patients with lower limb amputations with open wounds or active infection in residual or contralateral limbs.~* Patients with history of seizures.~* Patients with visual (self-reported) or cognitive impairment (assessed by the mini-mental state examination) that interferes with ability to interact with, participate in, and adhere to a computerized rehabilitation system.~* Any patient with a cardiac event in the last 6 months.~* Any patient with an active medical issue to minimize risk of exacerbating their condition.~* Lives more than 60 miles away from the Dallas VA Medical Center~* Any patient with the motion sickness induced by head mounted displays (HMDs) or immersive environment.~* Any patient experiencing the motion sickness induced by HMDs during the therapy session can also opt out of the study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Mixed Reality System for virtual mirror therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical Ruxolitinib Lichen Planus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Subjects must be able to understand and comply with the requirements of the study and communicate with the investigator.~Subjects must give written, signed, and dated informed consent before any study related activity is performed.~When appropriate, a legal representative will sign the informed consent according to local laws and regulation~Both men and women must be at least 18 years of age at the time of screening~Subjects must have clinical and histological features of LP~LP must involve between 2 and 20% of the BSA~Subjects must have a minimum of 10 lesions of LP~Subjects must have treatment naive cutaneous LP or treatment refractory disease, as defined by failure of at least one established treatment for LP~Failure of prior therapy Topical treatment Systemic immunosuppressant Oral metronidazole Oral sulfasalazine Oral retinoid

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- INCB018424 (Type: EXPERIMENTAL): INCB018424 Cream

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: REPAIR-AMI: Intracoronary Progenitor Cells in Acute Myocardial Infarction (AMI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with acute myocardial infarction (ST elevation in at least 2 leads \>= 0.2 mV in V1,V2 or V3 or \>= 0.1 mV in other leads), treated by one of the following procedures~  * Either acute PCI with stent implantation within 24 hours after symptom onset or~ * treatment with thrombolysis within 12 hours of symptom onset followed by PCI with stent implantation within 24 hours after thrombolysis.~* Acute PCI / stent implantation has been successful (residual stenosis visually \< 30% and TIMI flow \>= 2).~* At the time of inclusion patient does no longer require i.v. catecholamines or mechanical hemodynamic support (aortic balloon pump)~* Significant regional wall motion abnormality in LV angiogram at the time of acute PCI (ejection fraction \<= 45% on visual estimation).~* Maximal CK elevation \>= 400 U/l (measured at 37° C) with significant MB fraction \> 6%~* Age 18 - 80 Years~* Written informed consent~Exclusion Criteria:~* Regional wall motion abnormality outside the area involved in the index acute myocardial infarction.~* Need to revascularize additional vessels, outside the infarct artery.~* Arteriovenous malformations or aneurysms~* Active infection (CRP \> 10 mg/dl) now, or fever or diarrhea within last 4 weeks.~* Chronic inflammatory disease~* HIV infection or active hepatitis~* Neoplastic disease without documented remission within the past 5 years.~* Cerebrovascular insult within 3 months~* Impaired renal function (creatinine \> 2 mg/dl) at the time of cell therapy~* Significant liver disease (GOT \> 2x upper limit) or spontaneous INR \> 1,5)~* Anemia (hemoglobin \< 8.5 mg/dl)~* Platelet count \< 100.000/µl~* Hypersplenism~* Known allergy or intolerance to clopidogrel, heparin or abciximab.~* History of bleeding disorder~* Gastrointestinal bleeding within 3 months~* Major surgical procedure or traumata within 2 months~* Uncontrolled hypertension~* Pregnancy~* Mental retardation~* Previously performed stem / progenitor cell therapy~* Participation in another clinical trial within the last 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BMC (Type: EXPERIMENTAL): Intracoronary infusion of autologous bone marrow derived cells
- Placebo (Type: PLACEBO_COMPARATOR): Intracoronary infusion of Placebo medium

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have chronic plaque psoriasis based on a diagnosis of chronic plaque psoriasis for at least 6 months before baseline.~* Have moderate-to-severe psoriasis in the genital area at screening and baseline.~* Have plaque psoriasis in a nongenital area at screening and baseline.~* Have failed to respond to, or are intolerant of, at least 1 topical therapy used for treatment of psoriasis affecting the genital area.~* Must agree to use reliable method of birth control, which could include abstinence, during the study and for at least 12 weeks following the last dose of study drug.~Exclusion Criteria:~* Pustular, erythrodermic, and/or guttate forms of psoriasis.~* History of drug-induced psoriasis.~* Have recently received certain treatments for psoriasis (in particular, within the past 4 weeks but the restriction can go up to 12 months for some treatments).~* Have ever received treatment with ixekizumab, secukinumab, brodalumab, or another drug with a similar mode of action.~* Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to baseline and during the study.~* Are currently enrolled in any other clinical trial involving an investigational product.~* Serious disorder or illness other than plaque psoriasis.~* Active or history of malignant disease within 5 years prior to baseline.~* Serious infection within the last 3 months.~* Have received a live vaccine within 3 months of baseline or plan to do so during the study.~* Have received a vaccination with Bacillus Calmette-Guérin (BCG) within the past year.~* Pregnant or breastfeeding (lactating) women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ixekizumab (Type: EXPERIMENTAL): Blinded Treatment Period: 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab every 2 weeks (Q2W) SC from week 2 to week 10. At week 12, 80 mg ixekizumab and placebo given SC.~Open Label Period: 80 mg ixekizumab given SC every 4 weeks (Q4W) with an option for Q2W dosing starting at week 24, week 28 or week 40.
- Placebo (Type: PLACEBO_COMPARATOR): Blinded Treatment Period: Placebo given SC at baseline followed by placebo given SC Q2W from week 2 to week 10. At week 12, 160 mg ixekizumab given SC.~Open Label Period: 80 mg ixekizumab given SC Q4W with an option for Q2W dosing starting at week 24, week 28 or week 40.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Require lipid-modifying therapy for primary or secondary prevention of cardiovascular disease~* Fasting LDL-C ≥ 130 mg/dL for primary prevention or LDL-C ≥ 100 mg/dL for secondary prevention (history of HeFH and/or ASCVD)~* Treated with maximally tolerated statin therapy at stable dose for at least 4 weeks prior to screening~Exclusion Criteria:~* Total Fasting Triglyceride ≥ 400 mg/dL~* Renal Dysfunction or nephrotic syndrome or history of nephritis~* Significant cardiovascular disease or cardiovascular event within the past 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BA 180 mg + EZE 10 mg FDC (Type: EXPERIMENTAL): Bempedoic acid (BA) + ezetimibe (EZE) fixed-dose combination (FDC) 180 mg/10 mg tablets taken orally once daily for 12 weeks
- BA 180 mg (Type: EXPERIMENTAL): Bempedoic acid (BA) 180 mg tablets taken orally once daily for 12 weeks
- EZE 10 mg (Type: ACTIVE_COMPARATOR): Ezetimibe (EZE) 10 mg overencapsulated tablets taken orally once daily for 12 weeks
- Placebos (Type: PLACEBO_COMPARATOR): Placebos to match identical bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or identical bempedoic acid 180 mg tablet, or identical ezetimibe 10 mg capsule, taken orally, once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Testosterone and Athlete Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria are: healthy menstruating women; 18-35 yrs of age; BMI 19-25; non-smoking; having a moderate to high self-reported level of recreational physical activity (minimum of three hours of endurance and/or strength training per week); not taking hormonal contraception; and willing to use highly efficient non-hormonal contraception during the study such as:~* Intrauterine device~* Bilateral tubal occlusion~* Vasectomised partner~* Same-sex partner~* Sexual abstinence~Exclusion criteria are: the presence of cardiovascular, liver, biliary or renal disease; hyperlipidemia; uncontrolled high blood pressure; endocrinological disorder; oligomenorrhea (menstrual intervals of more than 6 weeks) or amenorrhea (no menstruation for at least 3 months); pregnancy; a history of thromboembolic disorder; any malignancy; and intake of hormonal contraception the last two months prior to the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: ACTIVE_COMPARATOR): Testosterone cream 1% (Andro-Feme® )
- Group B (Type: PLACEBO_COMPARATOR): Placebo cream

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, aged 18-65 years (both inclusive) at the time of signing informed consent~* Body mass index between 30.0 and 45.0 kilogram per meter square (kg/m\^2) (both inclusive)~Exclusion Criteria:~* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method~* Any disorder which in the investigator's opinion might jeopardise participant safety or compliance with the protocol~* Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, gastrointestinal, or endocrinological conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Semaglutide (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult males/Females aged 18\~80 years~2. Patient who are taking NSAIDs for the treatment of rheumatoid arthritis~3. Patients who belong to ACR functional class 1, 2, 3~Exclusion Criteria:~1. Patients who belong to ACR functional class 4~2. Patients who are hypersensitive to clinical trial medicines or excipient~3. Patients who have experience of Cerebrovascular bleeding, bleeding disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Pelubiprofen 30 mg (Type: EXPERIMENTAL): Pelubiprofen 30 mg, tid
- Celebrex 200 mg (Type: ACTIVE_COMPARATOR): Celebrex 200 mg, tid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Comparison of Ultrasound-Guided Percutaneous Platelet-Rich Plasma Injection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects with a diagnosis of tendinosis of the hip.~* Adult subjects who have been referred to Dr. Jacobson for the treatment of tendinosis by tenotomy.~Exclusion Criteria:~* pregnancy~* risk of bleeding due to anticoagulant medication~* presence of malignancy~* steroid injection less than 3 months before enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tenotomy Group (Type: ACTIVE_COMPARATOR): Subject enrolled in this arm will receive treatment for tendinitis and pain evaluation of pain pre and post treatment.
- Plasma Injection Group (Type: ACTIVE_COMPARATOR): Treatment is Ultrasound guided platelet rich plasma injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HepB-CpG Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Willing to provide informed consent~* Willing to comply with all study procedures and be available for the duration of the study~* Healthcare workers who have received at least 5 doses of hepatitis B vaccine with aluminum adjuvant and have antiHBs \< 10mIU/ml~* Females of childbearing potential will be asked about the possibility of pregnancy as is the standard of care for immunization services. If a female indicates that she may be pregnant, study participation will be postponed until pregnancy is completed or the female reports that she is not pregnant.~Exclusion Criteria:~* Women who are pregnant or planning on becoming pregnant during the study~* Allergy to the vaccine or a component of the vaccine~* Not suitable for study participation due to other reasons, such as inability or unwillingness to comply with the study procedures, at the discretion of the investigators

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Healthcare worker (Type: EXPERIMENTAL): Healthcare worker who has previously received at least 5 doses of hepatitis B vaccine with aluminum adjuvant (Recombivax B or Engerix B) and has an antibody to the hepatitis B surface antigen (antiHBs) that is less than 10 mIU/ml.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Quadruple Therapy for Triple Therapy Resistant Helicobacter Pylori Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent given by the patient~* Patients known to have H. pylori infection diagnosed by histopathology, rapid urease test and urea breath test~* Failure to respond to classical triple regime of amoxicillin 1gram, clarithromycin 500mg and omeprazole 20mg twice a day for 10-14 days as documented by repeat urea breath test done one month after eradication therapy~Exclusion Criteria:~* Evidence of any malignancy, gastric outlet syndrome, history of gastric surgery, chronic liver disease, severe chronic renal failure, or any major co-morbidity.~* known or suspected hypersensitivity to the medication used in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Quadruple Therapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years.~* Close contact of a pulmonary and/or laryngeal tuberculosis case.~* Written informed consent.~Exclusion Criteria:~* HIV infection.~* Immunosuppression other than HIV, such as decompensated liver disease, chronic renal failure, corticosteroids treatment, malignancy under chemotherapy therapy.~* Prior tuberculosis or positive TST.~* Strain resistant to Isoniazid (index case).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Arm A, Standard practice, TST (Type: ACTIVE_COMPARATOR): Participants allocated to screening as stablished by current practice (TST)
- Arm B, Experimental, TST plus QFT-IT (Type: EXPERIMENTAL): Participants allocated to screening with TST, and if positive, followed by QFT-IT to confirm tuberculosis infection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete